Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution.

The purpose of the present study was to compare the clinical results between preoperative chemoradiotherapy followed by surgery (CRT group) and surgery alone (Surgery group) by a randomized controlled study. Twenty-two patients were assigned to the CRT group and 23 to the Surgery group. A total radiation dose of 40 Gy was applied and in the same period, intravenous chemotherapy was performed using cisplatin (7 mg over 2 h) and 5-fluorouracil (5-FU; 350 mg over 24 h). Surgical treatment was performed in 20 patients in the CRT group except for two patients with bone metastasis after CRT. According to histological effects of primary tumors, the number of patient with Grades 1, 2 and 3 was 11, 7 and 3, respectively. Frequency of lymphatic and venous invasion was significantly lower in the CRT group than in the Surgery group. The 5-year survival rate was 57% in the CRT group and 41% in the Surgery group (P = 0.58). According to the histological effect in the CRT group, 5-year survival was 30% for Grade 1, 83% for Grade 2 and 100% for Grade 3 (P = 0.0069). This randomized trial did not demonstrate a statistically significant survival difference between the CRT group and the Surgery group.

[1]  B. Smithers,et al.  Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors' reply , 2005 .

[2]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[3]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Natsugoe,et al.  Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. , 2005, Oncology reports.

[5]  J. Ajani,et al.  Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. , 2005, The Annals of thoracic surgery.

[6]  J. Birkmeyer,et al.  Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. , 2005, Surgery.

[7]  H. Okumura,et al.  The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma , 2005, British Journal of Cancer.

[8]  J. Ajani,et al.  Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. , 2004, International journal of radiation oncology, biology, physics.

[9]  T. Aoki,et al.  Concurrent preoperative chemoradiotherapy for stage III or IV esophageal squamous carcinoma. , 2004, Oncology reports.

[10]  R. Malthaner,et al.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis , 2004, BMC medicine.

[11]  L. Kachnic,et al.  Esophageal cancer: Outcomes of surgery, neoadjuvant chemotherapy, and three‐dimension conformal radiotherapy , 2004, Journal of surgical oncology.

[12]  J. Lee,et al.  A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Coppola,et al.  Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy , 2004, Journal of Gastrointestinal Surgery.

[14]  H. Yamana,et al.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Rich,et al.  COX-2 Inhibitors as Radiation Sensitizers for Upper GI Tract Cancers: Esophagus, Stomach, and Pancreas , 2003, American journal of clinical oncology.

[16]  W. Mendenhall,et al.  Factors predictive of survival for esophageal carcinoma treated with preoperative radiotherapy with or without chemotherapy followed by surgery , 2003, Journal of surgical oncology.

[17]  E. Heath,et al.  Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. , 2002, The Annals of thoracic surgery.

[18]  Y. Doki,et al.  Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer , 2002, The British journal of surgery.

[19]  S. Natsugoe,et al.  Number of Lymph Node Metastases Determined by Presurgical Ultrasound and Endoscopic Ultrasound Is Related to Prognosis in Patients With Esophageal Carcinoma , 2001, Annals of surgery.

[20]  A. Livingstone,et al.  Neoadjuvant Therapy for Esophageal Cancer: Standard of Care or Elusive Myth? , 2001, The American surgeon.

[21]  V. Chiarion Sileni,et al.  Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma , 2001, Cancer.

[22]  H. Yamamori,et al.  Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. , 2001, Nutrition.

[23]  D. Faigel,et al.  Does neoadjuvant chemoradiation downstage esophageal carcinoma? , 2001, American journal of surgery.

[24]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Aikou,et al.  Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[26]  H. Okumura,et al.  Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. , 2000, Cancer letters.

[27]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[28]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[29]  M. Feith,et al.  Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma , 1998, Cancer.

[30]  A. Niendorf,et al.  Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. , 1997, The New England journal of medicine.

[31]  J. Bosset,et al.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. , 1997, The New England journal of medicine.

[32]  T. Aikou,et al.  Extranodal connective tissue invasion and the expression of desmosomal glycoprotein 1 in squamous cell carcinoma of the oesophagus. , 1997, British Journal of Cancer.

[33]  W. Mendenhall,et al.  Downstaging of Esophageal Cancer After Preoperative Radiation and Chemotherapy , 1995, Annals of surgery.

[34]  S. Natsugoe,et al.  Long‐Term Results of Subtotal Esophagectomy with Three‐Field Lymphadenectomy for Carcinoma of the Thoracic Esophagus , 1994, Annals of surgery.